IMPROVING MENTAL HEALTH AND WELLNESS

Lobe Sciences is a life sciences company focused on the research and development of psychedelic medicines. We focus on clinical development of devices and medicines to treat neurological disorders and brain traumas.

Developing and delivering solutions to improve the human condition.

Our mission is to identify and develop transformative new methods, medicines and devices to improve brain health and provide new pathways for treating brain injuries and neurological disorders.

We are undertaking the development of innovative medicines and devices to treat mental health disorders and improve well being while building a growing a portfolio of intellectual property to protect our technologies.

PSYCHEDELICS
EXPLAINED

Psychedelics and NAC

Psychedelics (serotonergic hallucinogens) are powerful psychoactive substances that alter perception and mood and affect numerous cognitive processes. They are generally considered physiologically safe and do not lead to dependence or addiction.

N-acetylcysteine (NAC) is a dietary supplement derived from the amino acid L-cysteine. Taking NAC increases the level of glutathione, a potent antioxidant and anti-inflammatory molecule, in cells. Glutathione’s function is to protect cellular compounds such as DNA and prevent damage to them from reactive oxygen species and inflammatory cytokines. It is also used as an antidote for acetaminophen overdose.

Our Approach

image

Micro-dosing Pscilocybin

Psilocybin combined with NAC for the treatment of mTBI and PTSD and other neurological disorders. Additionally, pairing them with odorants to create memory odor imprint pairing.

image

Micro-dosing MDMA

MDMA combined with NAC for the treatment of mTBI and PTSD and other neurological disorders. Additionally, pairing them with odorants to create memory odor imprint pairing.

image

Patented Pending Medical Devices

Medical Devices for immediate delivery of medicines directly to the Olfactory Bulb for best therapeutic outcomes.

image

Virtual Reality Integration

Virtual Reality Headset combined with Medical Devices to improve efficiency and raise response to treatment.

The Team

image

Philip J. Young

CEO & DIRECTOR

BIO

X

Philip J. Young

CEO & DIRECTOR

Mr. Young is an analytical and results driven life sciences executive who has successfully managed public and private companies through product development, international growth, commercialization and M&A transactions. He has served as a Director and Chief Executive Officer for public companies for the past 20 years where has had created significant shareholder value, built integrated scientific, manufacturing and commercial operations, directed successful M&A transactions and was responsible for generating more the $900M through acquisitions and equity financings. Mr. Young started his management career in the biopharmaceutical industry at Genentech Inc. where he was responsible for their cardiovascular and endocrine product launches sales and marketing.

image

Jonathan Gilbert

EXECUTIVE CHAIRMAN

BIO

X

Jonathan Gilbert

EXECUTIVE CHAIRMAN

Most recently, Jonathan was the founder and CEO at Tassili LifeSciences, Corp., a biotech firm conducting research utilizing Psilocybin. He was also the founder and CEO of Scythian Biosciences, Inc. from December of 2014 through May of 2018. Scythian was a publicly traded research and development company in Canada focusing on the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination, as well as strategic investments and partnerships across cultivation, distribution and retail of legal Cannabis.

image

Brian Zasitko

CHIEF FINANCIAL OFFICER

BIO

X

Brian Zasitko

CHIEF FINANCIAL OFFICER

Brian has over 13 years of experience across a variety of private and public sector companies in the cannabis, agriculture, manufacturing, and utility industries. He has extensive experience in financial reporting and corporate governance, as well as in the capital markets. Previously, Brian was a manager at Ernst & Young LLP, where he obtained his CPA, CA designation.

image

Maghsoud Dariani

CHIEF SCIENCE OFFICER

BIO

X

Maghsoud Dariani

CHIEF SCIENCE OFFICER

Prior to leading science and technology efforts at LOBE, Dariani was President of Focus Pharmaceuticals, Inc., where he managed the development and approval of drug products, achieving one FDA approval and bringing another to the clinical evaluation stage, then successfully negotiated the sale of the company in February 2003. Prior to Focus, Maghsoud was Vice President of the chiral pharmaceutical business unit at Celgene Corporation. During his twelve years at Celgene, he was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin, which are currently marketed by Novartis under the Focalin and Focalin XR trade names.

image

Michael Petter

DIRECTOR

BIO

X

Michael Petter

DIRECTOR

Michael is an accomplished leader and entrepreneur in the psychedelics and cannabis industry, co-founding and acting as a director of several companies that successfully completed M&A transactions. He holds a Bachelors in Computer Science from London University, is a Chartered Engineer and private pilot. Since January 2009, he has been the Managing Director of Eyvo eProcurement Solutions, a US-based private company that is a leading eProcurement provider in the SaaS space. He also runs a business mentoring program that assists businesses and individuals with change management. Mike was co-founder and director of Eleusian Biosciences Corp., which the Company acquired in July 2020. He also co-founded and was a director of Tassili Life Sciences Corp. which was acquired by CSE-listed Champignon Brands Inc. in March 2020. Mr. Petter has independent board experience being chairman of a compensation committee and as a member of an audit committee. His executive advisory skills focus on providing guidance on strategy, operations, finance and logistics.

image

Benjamin Kelmendi, MD

SCIENTIFIC ADVISOR

BIO

X

Benjamin Kelmendi, MD

SCIENTIFIC ADVISOR

Benjamin is a psychiatrist and an Associate Professor in the Department of Psychiatry at the Yale University School of Medicine. His primary clinical expertise is in PTSD, Depression, OCD, and the endocannabinoid system. He is the co-founder of the Yale Psychedelic Science Group. He leads a research program focused on the therapeutic potential of psychedelic medicines, across a range of psychiatric diagnoses. He is currently investigating the effects of psilocybin on the neurocircuitry implicated in the development, maintenance, and treatment of patients with OCD. He is also exploring the effects of MDMA on brain activation and neural network organization in PTSD to understand the relationship between MDMA-induced neural changes and the acute cognitive and behavioral effects of the drug.

image

Dr. Mark A. Geyer Ph.D

SCIENTIFIC ADVISOR

BIO

X

Dr. Mark A. Geyer Ph.D

SCIENTIFIC ADVISOR

Dr. Geyer is Distinguished Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego (UCSD) and directs the Neuropsychopharmacology Unit of the VISN 22 Veterans Administration Mental Illness Research, Clinical, and Education Center. He is respected internationally for his research on the psychophysiology, neurobiology, and pharmacotherapy of schizophrenia and bipolar disorder. Dr. Geyer’s broad experience as a researcher, grant reviewer, journal editor, and teacher lends invaluable scientific and professional expertise to several organizations, as he provides leadership to develop strong programs in the behavioral psychopharmacology and clinical applications of psychedelic agents.

image

Charles S. Grob, MD

SCIENTIFIC ADVISOR

BIO

X

Charles S. Grob, MD

SCIENTIFIC ADVISOR

Charles S. Grob, M.D. is Professor of Psychiatry and Pediatrics at the UCLA School of Medicine. He previously held faculty positions at the Johns Hopkins School of Medicine and the University of California at Irvine. He has conducted approved clinical research with psychedelics since the early 1990s. From 2004-2008 he was the Principal Investigator of the first study in several decades to examine the use of a psilocybin treatment model for patients with advanced-cancer anxiety. He has also conducted research into the range of effects of MDMA, in both normal volunteers and in a selected subject population of adult autistics with severe social anxiety. And, he has conducted a series of ayahuasca research studies in Brazil. Over the last thirty years Dr. Grob has published numerous articles on psychedelics in the medical and psychiatric literatures and he is the editor of Hallucinogens: A Reader (Putnam/Tarcher, 2002), co-editor (with Roger Walsh) of Higher Wisdom: Eminent Elders Explore the Continuing Impact of Psychedelics (SUNY Press, 2005) and co-editor (with James Grigsby) of the recently published Handbook of Medical Hallucinogens (Guilford Press, 2021). He is a founding board member of the Heffter Research Institute.

image

Albert “Skip” Rizzo, Ph.D

SCIENTIFIC ADVISOR

BIO

X

Albert “Skip” Rizzo, Ph.D

SCIENTIFIC ADVISOR

Albert “Skip” Rizzo is a clinical psychologist and Director of Medical VR at the University of Southern California Institute for Creative Technologies. He is also a Research Professor with the USC Dept. of Psychiatry and School of Gerontology. Over the last 25 years, Skip has conducted research on the design, development and evaluation of Virtual Reality systems targeting the areas of clinical assessment, treatment, and rehabilitation across the domains of psychological, cognitive and motor functioning in both healthy and clinical populations. This work has focused on PTSD, TBI, Autism, ADHD, Alzheimer’s disease, stroke and other clinical conditions. He has also driven an extensive research program on the use of intelligent virtual human agents for clinical training, healthcare information support, and clinical assessment. In spite of the diversity of these clinical R&D areas, the common thread that drives all of his work with digital technologies involves the study of how Virtual Reality simulations can be usefully applied to human healthcare beyond what’s possible with traditional 20th Century methods.

image

Ilan Hayman

ADVISOR

BIO

X

Ilan Hayman

ADVISOR

Ilan has played a pivotal role in the General Management of healthcare businesses including a private cosmetic surgery chain and the commercialisation of a breakthrough skincare range. He successfully led the development of these products from concept through to production commercialisation. Most recently Ilan oversaw a group of national medical centers. His career into operations management was triggered by his valuable experience as part of the Risk and Controls Solutions practice at PricewaterhouseCoopers (PwC). Specifically, Ilan’s passion is assisting the medical fraternity in their practice management and business administration functions. Ilan’s ambition is to work in a role that utilises his analysis expertise enriched by his exposure to the commercial side of business. Ilan has a passion for assisting community organisations and sits on several boards of not for profit organisations. He also holds Bronze and Silver Duke of Edinburgh awards and brings along a unique set of community and industry related experience.

image

Bart Oates

ADVISOR

BIO

X

Bart Oates

ADVISOR

Bart Oates Esq. is a three-time Superbowl Champion, who graduated magna cum laude with a Juris Doctor degree from Seton Hall during his off season. Prior to his NFL career, he earned a BS in Accounting from the Marriott School of Business at BYU and was inducted into their athletic Hall of Fame in 1992. Bart was selected to five Pro Bowls during his NFL career and to the UPI All-NFC team three times. Bart is now the President of the NFL Alumni Association which offers former players a diverse package of medical, business, and legal services to help keep them and their families healthy, productive, and connected to their former teammates.

image

Gilberto Jesús Mendoza

ADVISOR

BIO

X

Gilberto Jesús Mendoza

ADVISOR

Gilberto Jesús Mendoza is currently the President of the World Boxing Association. Mr. Mendoza began his career as a lawyer and an engineer and has been working with the WBA since 2015. His priority has always been to give opportunities to the most vulnerable regions of the world. He has spent time in close contact with athletes since he was a child and has actively participated in the intention to rescue amateur boxing. Mr. Mendoza is the proud creator of “Un Solo Boxeo” (Only One Boxing), a program that promotes the integration of professional boxing. He also created the Future WBA Champion, a project that has given space to thousands of boxers in their preparation stage for the Tokyo Olympic Games. Mr. Mendoza’s goal is the growth and development of boxing, as well as its adaptation to change.